{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-011922","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2026-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.637273+00:00","generated_at":"2026-05-15T09:32:47.546725+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ernexa Therapeutics receives Nasdaq delisting bid-price notice; ineligible for cure due to prior reverse split","bullets":["Received Nasdaq notice on March 18, 2026 for failure to maintain $1.00 minimum bid price for 30 consecutive business days.","Company not eligible for standard 180-day compliance period under Rule 5810(c)(3)(A)(iv) due to reverse stock split within past year.","Intends to request hearing before Nasdaq Hearing Panel; request stays suspension/delisting pending panel decision and possible 180-day extension.","No assurance that panel will grant extension or that securities (ERNA, ERNAW) will remain listed on Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-011922","json":"https://secwatch.observer/filing/0001493152-26-011922.json","markdown":"https://secwatch.observer/filing/0001493152-26-011922.md","text":"https://secwatch.observer/filing/0001493152-26-011922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/0001493152-26-011922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:32:47.546725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12405d8e0fe58974b7678c9ad7b0983ce11c623e","claim":"Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).","evidence_excerpt":"March 18, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “ Company ”, “ we ”, “ us ”, or “ our ”), received a written notice (the “ Notice ”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Nasdaq staff (the “ Staff ”) determined that the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in violation of Nasdaq Listing Rule 5550(a)(2) (the “ Rule ”). While companies are typically afforded a 180-calendar day compliance period, as specified under Nasdaq L","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/0001493152-26-011922-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-063575","ticker":"ISPC","company_name":"iSpecimen Inc.","filed_at":"2026-06-01T21:00:15+00:00","headline":"iSpecimen flagged for Nasdaq equity shortfall; equity $814K vs $2.5M minimum","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063575","json":"https://secwatch.observer/filing/0001213900-26-063575.json","markdown":"https://secwatch.observer/filing/0001213900-26-063575.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/0001213900-26-063575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/ea0292875-8k_ispecimen.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"March 18, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “ Company ”, “ we ”, “ us ”,\nor “ our ”), received a written notice (the “ Notice ”) from the Nasdaq Listing Qualifications Department\nof The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Nasdaq staff (the “ Staff ”) determined\nthat the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in\nviolation of Nasdaq Listing Rule 5550(a)(2) (the “ Rule ”). While companies are typically afforded a 180-calendar day\ncompliance period, as specified under Nasdaq L","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/0001493152-26-011922-index.htm","comparable_excerpt":"May 29, 2026, iSpecimen Inc. (the “Company”)\nreceived a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires a minimum\nof $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Capital Market”). As reported in the Company’s Quarterly Report\non Form 10-Q for the period ended March 31, 2026, the Company had stockholders’ equity of $814,038. Nasdaq noted that, as of May\n29, 2026, the Company doe","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/0001213900-26-063575-index.htm"}},{"accession":"0001493152-26-026442","ticker":"HWH","company_name":"HWH International Inc.","filed_at":"2026-05-29T21:21:49+00:00","headline":"HWH International receives Nasdaq deficiency notice for equity below $2.5M threshold","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026442","json":"https://secwatch.observer/filing/0001493152-26-026442.json","markdown":"https://secwatch.observer/filing/0001493152-26-026442.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1897245/000149315226026442/0001493152-26-026442-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1897245/000149315226026442/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"March 18, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “ Company ”, “ we ”, “ us ”,\nor “ our ”), received a written notice (the “ Notice ”) from the Nasdaq Listing Qualifications Department\nof The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Nasdaq staff (the “ Staff ”) determined\nthat the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in\nviolation of Nasdaq Listing Rule 5550(a)(2) (the “ Rule ”). While companies are typically afforded a 180-calendar day\ncompliance period, as specified under Nasdaq L","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/0001493152-26-011922-index.htm","comparable_excerpt":"May 29, 2026 HWH International Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’\nequity requirement for continued listing on the Nasdaq Capital Market, under Listing Rule 5550(b)(1) because the Company’s stockholders’\nequity of $2,078,220 as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026 was below the\nrequired minimum of $2.5 million, and because, as of May 29, 2026, the Company did","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1897245/000149315226026442/0001493152-26-026442-index.htm"}},{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"March 18, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “ Company ”, “ we ”, “ us ”,\nor “ our ”), received a written notice (the “ Notice ”) from the Nasdaq Listing Qualifications Department\nof The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Nasdaq staff (the “ Staff ”) determined\nthat the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in\nviolation of Nasdaq Listing Rule 5550(a)(2) (the “ Rule ”). While companies are typically afforded a 180-calendar day\ncompliance period, as specified under Nasdaq L","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/0001493152-26-011922-index.htm","comparable_excerpt":"May 27, 2026, Actinium Pharmaceuticals, Inc.\n(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating\nthat the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company\nGuide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more\nif it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,\n2026, the Company reported stockholders’ equity of approximately","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm"}},{"accession":"0001683168-26-004399","ticker":"CSAI","company_name":"CLOUDASTRUCTURE, INC.","filed_at":"2026-05-29T21:09:11+00:00","headline":"Cloudastructure receives Nasdaq delinquency notice for late Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004399","json":"https://secwatch.observer/filing/0001683168-26-004399.json","markdown":"https://secwatch.observer/filing/0001683168-26-004399.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/0001683168-26-004399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/cloud_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"March 18, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “ Company ”, “ we ”, “ us ”,\nor “ our ”), received a written notice (the “ Notice ”) from the Nasdaq Listing Qualifications Department\nof The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Nasdaq staff (the “ Staff ”) determined\nthat the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in\nviolation of Nasdaq Listing Rule 5550(a)(2) (the “ Rule ”). While companies are typically afforded a 180-calendar day\ncompliance period, as specified under Nasdaq L","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/0001493152-26-011922-index.htm","comparable_excerpt":"May 26, 2026, Cloudastructure,\nInc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq\nStock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for\nthe period ended March 31, 2026 (“Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which\nrequires timely filing of all required periodic financial reports with the Securities and Exchange Commission. The Company requires additional\ntime to review and confirm the accounting treatment for its outstand","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/0001683168-26-004399-index.htm"}},{"accession":"0001477932-26-003501","ticker":"EDBL","company_name":"Edible Garden AG Inc","filed_at":"2026-05-29T21:00:24+00:00","headline":"Edible Garden receives Nasdaq delisting notice for bid price non-compliance; intends to appeal","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-003501","json":"https://secwatch.observer/filing/0001477932-26-003501.json","markdown":"https://secwatch.observer/filing/0001477932-26-003501.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1809750/000147793226003501/0001477932-26-003501-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1809750/000147793226003501/edbl_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"March 18, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “ Company ”, “ we ”, “ us ”,\nor “ our ”), received a written notice (the “ Notice ”) from the Nasdaq Listing Qualifications Department\nof The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Nasdaq staff (the “ Staff ”) determined\nthat the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in\nviolation of Nasdaq Listing Rule 5550(a)(2) (the “ Rule ”). While companies are typically afforded a 180-calendar day\ncompliance period, as specified under Nasdaq L","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/0001493152-26-011922-index.htm","comparable_excerpt":"May 27, 2026, Edible Garden AG Incorporated (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for at least 30 consecutive business days, the Company no longer meets Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least $1 per share (the “Bid Price Rule”). Under Nasdaq Listing Rule 5810(c)(3)(A)(iv), because the Company has effected a reverse stock split over the prior one-year per","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1809750/000147793226003501/0001477932-26-003501-index.htm"}},{"accession":"0001193805-26-000723","ticker":"GURE","company_name":"GULF RESOURCES, INC.","filed_at":"2026-05-29T20:45:30+00:00","headline":"Gulf Resources receives Nasdaq delisting notice for late Q1 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-000723","json":"https://secwatch.observer/filing/0001193805-26-000723.json","markdown":"https://secwatch.observer/filing/0001193805-26-000723.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/0001193805-26-000723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/e665526_8k-gulfresources.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"March 18, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “ Company ”, “ we ”, “ us ”,\nor “ our ”), received a written notice (the “ Notice ”) from the Nasdaq Listing Qualifications Department\nof The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Nasdaq staff (the “ Staff ”) determined\nthat the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in\nviolation of Nasdaq Listing Rule 5550(a)(2) (the “ Rule ”). While companies are typically afforded a 180-calendar day\ncompliance period, as specified under Nasdaq L","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/0001493152-26-011922-index.htm","comparable_excerpt":"May 26, 2026, Gulf Resources\n(the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq\nStock Market LLC (“Nasdaq”), indicating that, as a result of not having timely filed its quarterly report on Form 10-Q for\nthe quarter ended March 31, 2026 (the “Form 10-Q”), and the Company remains delinquent in filing its annual report on Form\n10-K for the year ended December 31, 2025 (the “Initial Delinquent Filing”), the Company is in non-compliance with Nasdaq\nListing Rule 5250(c)(1), which requires timely filing all required periodic financial reports wit","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/0001193805-26-000723-index.htm"}},{"accession":"0001654954-26-005548","ticker":"ONFO","company_name":"Onfolio Holdings, Inc","filed_at":"2026-05-29T20:30:53+00:00","headline":"Onfolio receives Nasdaq delisting notice for insufficient equity ($1.22M vs $2.5M min)","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-26-005548","json":"https://secwatch.observer/filing/0001654954-26-005548.json","markdown":"https://secwatch.observer/filing/0001654954-26-005548.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1825452/000165495426005548/0001654954-26-005548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1825452/000165495426005548/onfo_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"March 18, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “ Company ”, “ we ”, “ us ”,\nor “ our ”), received a written notice (the “ Notice ”) from the Nasdaq Listing Qualifications Department\nof The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Nasdaq staff (the “ Staff ”) determined\nthat the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in\nviolation of Nasdaq Listing Rule 5550(a)(2) (the “ Rule ”). While companies are typically afforded a 180-calendar day\ncompliance period, as specified under Nasdaq L","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/0001493152-26-011922-index.htm","comparable_excerpt":"May 26, 2026, Onfolio Holdings Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) informing the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market. The Notice states that the Company’s Quarterly Report on Form 10-Q for the for the period ended March 31, 2026 reported stockholders’ equity of $1,216,603. As of the date of the Notice","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1825452/000165495426005548/0001654954-26-005548-index.htm"}},{"accession":"0001213900-26-062172","ticker":"RR","company_name":"RICHTECH ROBOTICS INC.","filed_at":"2026-05-28T20:49:32+00:00","headline":"Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062172","json":"https://secwatch.observer/filing/0001213900-26-062172.json","markdown":"https://secwatch.observer/filing/0001213900-26-062172.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/0001213900-26-062172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/ea0292546-8k_richtech.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"March 18, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “ Company ”, “ we ”, “ us ”,\nor “ our ”), received a written notice (the “ Notice ”) from the Nasdaq Listing Qualifications Department\nof The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Nasdaq staff (the “ Staff ”) determined\nthat the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in\nviolation of Nasdaq Listing Rule 5550(a)(2) (the “ Rule ”). While companies are typically afforded a 180-calendar day\ncompliance period, as specified under Nasdaq L","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/0001493152-26-011922-index.htm","comparable_excerpt":"May 22, 2026, Richtech\n Robotics Inc., a Nevada corporation (the “ Company ”) received a notice (the “ Notice ”) from the Listing\n Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company is not in compliance\n with Nasdaq Listing Rule 5250(c)(1) (the “ Rule ”), because it has not timely filed its Quarterly Report on Form 10-Q\n for the period ended March 31, 2026 (the “ Form 10-Q ”) with the U.S. Securities and Exchange Commission (the “ SEC ”). The\n Rule requires listed companies to timely file all required periodic financial reports with the SEC. The Com","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/0001213900-26-062172-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}